Get the right diagnosis the first time
We’re committed to helping healthcare workers like you navigate the challenges of diagnosing infectious diseases. That’s why we’ve developed an easy-to-use, automated diagnostic testing system that can help eliminate the guesswork and make your job easier. Our tests use multiplex PCR technology – also known as syndromic testing – that can quickly survey many different pathogens in a single patient sample. With syndromic testing, you get the answers you need, when you need them. And your patients get better care, faster.
Latest insights – webinars, stories and more
-
Outrunning viruses with molecular toolsClinical virologist, Dr. Allison Glass, thrives on fast-paced results, whether she’s running an ultramarathon or running a state-of-the-art molecular diagnostics lab. Learn how she leverages the fast results provided by multiplex syndromic testing to stay one step ahead of viruses. -
Take your diagnostics to new heightsMeet the QIAstat-Dx Rise, the new higher-throughput member of the QIAstat-Dx family. This automated powerhouse combines a quick and easy workflow with random access capabilities for increased testing capacity. -
Prepare for gastroenteritis season with our updated GI panelWe’re proud to release our new and improved QIAstat-Dx Gastrointestinal Panel 2 to help you meet the challenges of gastroenteritis this summer and beyond. -
New rapid test for meningitis/encephalitisRapid diagnosis of central nervous system infections is crucial for successful patient outcomes. That's why we've introduced a new syndromic panel that can differentiate 15 pathogens in around 1 hour. -
Q&A with the experts: Syndromic testing for infectious diseasesHow is syndromic testing currently being used in the clinic and how will it impact diagnostics going forward? Read the article to learn what three experts, including prof Dr med Stephan Gehring, had to say.
Why choose syndromic testing as a diagnostic tool?
-
Laboratory benefits- Easy to set up a test, with less than one minute hands-on time
- Increased analytical sensitivity1,2,3 versus traditional methods
- Ct data and amplification curves visible for detected pathogens
-
Patient benefits- Comprehensive results for more than 20 pathogens with faster turnaround times4 can support faster clinical decision making
- Associated with reduced hospital length of stay5, improved patient management6 and better outcomes7
-
Antimicrobial stewardship benefits- Comprehensive results allow causative pathogens to be identified quickly
- Supports the use of a targeted therapeutic approach to reduce inappropriate antibiotic use8 and antibiotic duration8
-
Healthcare cost benefits- A reduction in the need for follow-up testing, shorter hospital stays and more efficient testing can reduce overall healthcare costs9
Voices from the field – how medical professionals are using syndromic diagnostics
Celestin Alexis Agbessi, M.D., Bichat-Claude Bernard Hospital, Paris
Michelle Volk, CEO and president of Great Lakes Labs, Indiana, USA
Joshua Arant, Founder and Chief Operations Officer, Mako Medical
Featured – resources for infectious disease diagnostics
-
A simple syndromic workflowSee how quick and intuitive syndromic testing can be. Use this interactive demo to try out the QIAstat-Dx Analyzer for yourself. -
Explore our library of webinarsWatch our most recent webinars to learn how experts have incorporated syndromic testing into their diagnostic approach. Plus, get the latest insights on molecular diagnostics for infectious diseases. -
Dive into articlesGet the latest information on syndromic testing for infectious diseases, including insights on new publications and developments.
References
- Yalamanchili H, et al. (2018) Gastroenterol Hepatol, 14(11):646-652
- Binnicker M. Multiplex. (2015) J. Clin Microbiology, 53(12):3723-3728
- Macfarlane-Smith L, et al. (2018) Gastrointestinal Infections, 34(1):19-2
- Echavarria M, et al. (2018) J Clin Virol, 108:90–95
- Beal S G, et al. (2018) J Clin Microbiol, 18;56(1)
- Bouzid D, et al. (2020) J Hospital Infection, 337-338
- Iroh Tam PY, et al. (2017) Children (Basel), 4(1)
- Zhu et al. (2018) Clin Pediatr, 58(2): 185-190
- Martinez RM, et al. (2016) Clinical Virology Symposium, Poster #C-368
*Some features require a QIAstat-Dx Connectivity plan. Flexible plans are available to meet your lab’s needs.
The QIAstat-Dx Analyzer, QIAstat-Dx Rise and QIAstat-Dx panels are intended for in vitro diagnostic use.
The QIAstat-Dx ME Panel is indicated as an aid in the diagnosis of specific agents that cause meningitis and/or encephalitis, and results must be used in conjunction with other clinical, epidemiological, and laboratory data. Results from the QIAstat-Dx ME Panel are not intended to be used as the sole basis for diagnosis, treatment, or other patient management decisions. Positive results do not rule out co-infection with organisms not included in the QIAstat-Dx ME Panel. The agent or agents detected may not be the definite cause of the disease. Negative results do not preclude central nervous system (CNS) infection.
The QIAstat-Dx ME Panel is intended for in vitro diagnostic use by laboratory professionals only.
Product availability may differ from country to country based on regulations and approvals. Contact your country representative for further details.
For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit instructions for use or user manual.